Portfolio Design Labs LLC Takes Position in Colgate-Palmolive (NYSE:CL)

Portfolio Design Labs LLC purchased a new stake in Colgate-Palmolive (NYSE:CLFree Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 5,936 shares of the company’s stock, valued at approximately $473,000.

A number of other institutional investors and hedge funds also recently modified their holdings of CL. Vest Financial LLC increased its stake in Colgate-Palmolive by 25.1% during the 4th quarter. Vest Financial LLC now owns 370,071 shares of the company’s stock worth $29,498,000 after purchasing an additional 74,337 shares in the last quarter. Central Bank & Trust Co. increased its stake in Colgate-Palmolive by 22.1% during the 4th quarter. Central Bank & Trust Co. now owns 1,383 shares of the company’s stock worth $110,000 after purchasing an additional 250 shares in the last quarter. Dynamic Advisor Solutions LLC increased its stake in Colgate-Palmolive by 9.2% during the 4th quarter. Dynamic Advisor Solutions LLC now owns 10,808 shares of the company’s stock worth $864,000 after purchasing an additional 910 shares in the last quarter. Sarasin & Partners LLP increased its stake in Colgate-Palmolive by 1.2% during the 4th quarter. Sarasin & Partners LLP now owns 4,053,634 shares of the company’s stock worth $323,115,000 after purchasing an additional 49,980 shares in the last quarter. Finally, Cornerstone Wealth Management LLC increased its stake in Colgate-Palmolive by 2.5% during the 4th quarter. Cornerstone Wealth Management LLC now owns 7,170 shares of the company’s stock worth $571,000 after purchasing an additional 172 shares in the last quarter. 80.41% of the stock is owned by institutional investors.

Colgate-Palmolive Price Performance

Colgate-Palmolive stock traded down $0.28 during trading hours on Wednesday, reaching $91.66. 653,486 shares of the stock were exchanged, compared to its average volume of 4,531,410. The company has a market cap of $75.20 billion, a P/E ratio of 29.10, a price-to-earnings-growth ratio of 3.44 and a beta of 0.40. The company has a current ratio of 1.06, a quick ratio of 0.70 and a debt-to-equity ratio of 13.21. Colgate-Palmolive has a twelve month low of $67.62 and a twelve month high of $95.59. The stock has a 50 day moving average of $90.54 and a two-hundred day moving average of $84.74.

Colgate-Palmolive (NYSE:CLGet Free Report) last posted its earnings results on Friday, April 26th. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.96 billion. Colgate-Palmolive had a net margin of 13.22% and a return on equity of 485.40%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.73 earnings per share. Equities analysts expect that Colgate-Palmolive will post 3.53 EPS for the current fiscal year.

Colgate-Palmolive Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 15th. Investors of record on Monday, April 22nd were issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 2.18%. The ex-dividend date of this dividend was Friday, April 19th. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.48. Colgate-Palmolive’s dividend payout ratio (DPR) is 63.29%.

Insider Activity at Colgate-Palmolive

In other Colgate-Palmolive news, insider Sally Massey sold 12,226 shares of the stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $94.06, for a total transaction of $1,149,977.56. Following the completion of the sale, the insider now owns 13,924 shares of the company’s stock, valued at approximately $1,309,691.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider John W. Kooyman sold 3,497 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $93.47, for a total transaction of $326,864.59. Following the completion of the sale, the insider now owns 3,181 shares of the company’s stock, valued at approximately $297,328.07. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sally Massey sold 12,226 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $94.06, for a total transaction of $1,149,977.56. Following the sale, the insider now directly owns 13,924 shares of the company’s stock, valued at approximately $1,309,691.44. The disclosure for this sale can be found here. 0.37% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CL has been the subject of a number of recent research reports. Evercore ISI upped their price target on Colgate-Palmolive from $90.00 to $96.00 and gave the stock an “outperform” rating in a research report on Monday, April 8th. Morgan Stanley upped their price target on Colgate-Palmolive from $101.00 to $103.00 and gave the stock an “overweight” rating in a research report on Tuesday. Barclays increased their price objective on Colgate-Palmolive from $84.00 to $85.00 and gave the company an “equal weight” rating in a report on Tuesday, April 30th. Bank of America increased their price objective on Colgate-Palmolive from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, April 29th. Finally, The Goldman Sachs Group initiated coverage on Colgate-Palmolive in a report on Friday, March 1st. They issued a “buy” rating and a $93.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $92.94.

View Our Latest Analysis on Colgate-Palmolive

About Colgate-Palmolive

(Free Report)

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

See Also

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.